Don't Jump to an SGLT2 Inhibitor for Heart Failure

November 2019

You'll hear debate about whether to use an SGLT2 inhibitor (Farxiga, etc) to treat heart failure...in patients withOUT diabetes.

Prior evidence suggests that patients WITH diabetes and CV disease or CV risks have fewer heart failure hospitalizations with Farxiga (dapagliflozin), Invokana (canagliflozin), or Jardiance (empagliflozin).

New evidence suggests Farxiga may benefit some heart failure patients...whether or not they have type 2 diabetes.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Safety Put Concerns About Ranitidine and Drug Safety in Perspective
Diabetes Temper Buzz About the First Oral GLP-1 Agonist, Rybelsus
Medicare Avoid Pitfalls With Medicare Rxs for DME
Pain Management Clarify How to Treat Acute Pain in Patients on Buprenorphine/Naloxone
Heart Failure Don't Jump to an SGLT2 Inhibitor for Heart Failure
Alcohol Be Ready to Answer the Question, "Is It Okay to Drink Alcohol With This Med?"
HIV & AIDS Know How Descovy and Truvada Stack Up for HIV Pre-Exposure Prophylaxis (PrEP)
Hypoglycemia Compare Baqsimi or Gvoke With IM Glucagon for Severe Hypoglycemia
Breast Cancer Weigh Pros and Cons of Meds for Primary Prevention of Breast Cancer
Dermatology Set Realistic Expectations for Patients Asking About Scar Treatments

Don't Jump to an SGLT2 Inhibitor for Heart Failure

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents